The agency has granted the drug and CDx priority review, which Myriad expects to conclude during its fiscal third-quarter ending March 31, 2018.
The funding will go toward bringing the BA100 test to clinicians. The test can identify patients most likely to respond to the standard of care chemotherapy treatment.
Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors.
The company is developing a test based on computational quantitation of a subtype cells called MDSCs, which play a role in the tumor microenvironment.
Its tests use FTIR to measure the spectra from biochemical changes in peripheral blood mononuclear cells, along with a proprietary technique that analyzes results.
Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.
The group said that progress in developing the test for a broad range of medical conditions will be driven in part by frequent donations of urine samples.
The company said that more than 95 percent of eligible early-stage breast cancer patients can now have the test paid by insurance.
The agreement is to support the company’s analytical and preanalytical research and assist in its trials aimed at a number of cancers.